Glivec licence extension

The licence for Glivec (imatinib) has been extended to include its use as an adjuvant post-surgery treatment in patients with KIT (CD117)-positive gastrointestinal stromal tumours (GIST) who are at significant risk of the cancer returning after surgery.

The recommended dose of Glivec for this new indication is 400mg once daily. 

View Glivec drug record

Further information: Novartis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases